Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder

Bibliography

• WILENS TE, BIEDERMAN J, BROWN S et al.: Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(3):262-268.
   PubMed Web of Science ®Google Scholar
• SPENCER T, BIEDERMAN J, WILENS T: Attention-deficit/hyperactivity disorder and comorbidity. Pediatr. Clin. North Am. (1999) 46(5):915-927.
   PubMed Web of Science ®Google Scholar
• BUSCH B, BIEDERMAN J, COHEN LG et al.: Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatr. Serv. (2002) 53(9):1103-1111.
   PubMed Web of Science ®Google Scholar
• MILBERGER S, BIEDERMAN J, FARAONE SV, MURPHY J, TSUANG MT: Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Am. J. Psychiatry (1995) 152(12):1793-1799.
   PubMed Web of Science ®Google Scholar
• A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry (1999) 56(12):1073-1086.
   PubMed Web of Science ®Google Scholar
• KLEIN RG, ABIKOFF H, KLASS E et al.: Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch. Gen. Psychiatry (1997) 54(12):1073-1080.
   PubMed Web of Science ®Google Scholar
• GADOW KD, SVERD J, SPRAFKIN J, NOLAN EE, GROSSMAN S: Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch. Gen. Psychiatry (1999) 56(4):330-336.
   PubMed Web of Science ®Google Scholar
• PELHAM WE, GNAGY EM, BURROWS-MACLEAN L et al.: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics (2001) 107(6):E105.
   PubMedGoogle Scholar
• SPENCER TJ, ABIKOFF HB, CONNOR DF et al.: Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin. Ther. (2006) 28(3):402-418.
   PubMed Web of Science ®Google Scholar
• NEWCORN JH, SPENCER TJ, BIEDERMAN J, MILTON DR, MICHELSON D: Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(3):240-248.
   PubMed Web of Science ®Google Scholar
• HAZELL P, ZHANG S, WOLANCZYK T et al.: Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur. Child Adolesc. Psychiatry (2006) 15(2):105-110.
   Google Scholar
• CONNOR DF, GLATT SJ, LOPEZ ID, JACKSON D, MELLONI RH Jr: Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(3):253-261.
   PubMed Web of Science ®Google Scholar
• KOLKO DJ, BUKSTEIN OG, BARRON J: Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(5):578-586.
   PubMed Web of Science ®Google Scholar
• EAPEN V, GURURAJ AK: Risperidone treatment in 12 children with developmental disorders and attention-deficit/hyperactivity disorder. Prim. Care Companion J. Clin. Psychiatry (2005) 7(5):221-224.
   Google Scholar
• AMAN MG, BINDER C, TURGAY A: Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J. Child Adolesc. Psychopharmacol. (2004) 14(2):243-254.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, MICK E, WOZNIAK J et al.: Can a subtype of conduct disorder linked to bipolar disorder be identified? Integration of findings from the Massachusetts General Hospital Pediatric Psychopharmacology Research Program. Biol. Psychiatry (2003) 53(11):952-960.
   PubMedGoogle Scholar
• JENSEN PS, HINSHAW SP, KRAEMER HC et al.: ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(2):147-158.
   PubMed Web of Science ®Google Scholar
• SOUZA I, PINHEIRO MA, MATTOS P: [Anxiety disorders in an attention-deficit/hyperactivity disorder clinical sample.]. Arq. Neuropsiquiatr. (2005) 63(2B):407-409.
   PubMed Web of Science ®Google Scholar
• PLISZKA SR: Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J. Am. Acad. Child Adolesc. Psychiatry (1989) 28(6):882-887.
   PubMed Web of Science ®Google Scholar
• DIAMOND IR, TANNOCK R, SCHACHAR RJ: Response to methylphenidate in children with ADHD and comorbid anxiety. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(4):402-409.
   PubMed Web of Science ®Google Scholar
• BARRICKMAN L, NOYES R, KUPERMAN S, SCHUMACHER E, VERDA M: Treatment of ADHD with fluoxetine: a preliminary trial. J. Am. Acad. Child Adolesc. Psychiatry (1991) 30(5):762-767.
   PubMed Web of Science ®Google Scholar
• ABIKOFF H, MCGOUGH J, VITIELLO B et al.: Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(5):418-427.
   PubMed Web of Science ®Google Scholar
• KRATOCHVIL CJ, NEWCORN JH, ARNOLD LE et al.: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(9):915-924.
   PubMed Web of Science ®Google Scholar
• DALY JM, WILENS T: The use of tricyclic antidepressants in children and adolescents. Pediatr. Clin. North Am. (1998) 45(5):1123-1135.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, MICK E, FARAONE SV: Depression in attention deficit hyperactivity disorder (ADHD) children: ‘true’ depression or demoralization? J. Affect. Disord. (1998) 47(1-3):113-122.
   PubMed Web of Science ®Google Scholar
• FINDLING RL: Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J. Child Adolesc. Psychopharmacol. (1996) 6(3):165-175.
   PubMed Web of Science ®Google Scholar
• GAMMON G, BROWN T: Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depression. J. Child Adolesc. Psychopharmacol. (1993) 3:1-10.
   PubMedGoogle Scholar
• DAVISS WB, BENTIVOGLIO P, RACUSIN R et al.: Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(3):307-314.
   PubMed Web of Science ®Google Scholar
• HAZELL P, O’CONNELL D, HEATHCOTE D et al.: Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev (2002) 2:CD002317.
   PubMedGoogle Scholar
• HUGHES CW, EMSLIE GJ, CRISMON ML et al.: The Texas Children’s Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(11):1442-1454.
   Google Scholar
• EMSLIE GJ, HUGHES CW, CRISMON ML et al.: A feasibility study of the childhood depression medication algorithm: the Texas Children’s Medication Algorithm Project (CMAP). J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(5):519-527.
   PubMed Web of Science ®Google Scholar
• PLISZKA SR, GREENHILL LL, CRISMON ML et al.: The Texas Children’s Medication Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part I. Attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39(7):908-919.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, MICK E, FARAONE SV et al.: Pediatric mania: a developmental subtype of bipolar disorder? Biol. Psychiatry (2000) 48(6):458-466.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, GRACIOUS BL, MCNAMARA NK et al.: Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord (2001) 3(4):202-210.
   PubMed Web of Science ®Google Scholar
• GELLER B, ZIMERMAN B, WILLIAMS M et al.: Diagnostic characteristics of 93 cases of a prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and comorbid attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. (2000) 10(3):157-164.
   PubMed Web of Science ®Google Scholar
• WOZNIAK J, BIEDERMAN J, KIELY K et al.: Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34(7):867-876.
   PubMed Web of Science ®Google Scholar
• KOWATCH RA, FRISTAD M, BIRMAHER B et al.: Treatment guidelines for children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(3):213-235.
   PubMed Web of Science ®Google Scholar
• GELLER B, SUN K, ZIMERMAN B et al.: Complex and rapid-cycling in bipolar children and adolescents: a preliminary study. J. Affect. Disord. (1995) 34(4):259-268.
   PubMed Web of Science ®Google Scholar
• BUTLER SF, ARREDONDO DE, MCCLOSKEY V: Affective comorbidity in children and adolescents with attention deficit hyperactivity disorder. Ann. Clin. Psychiatry (1995) 7(2):51-55.
   PubMedGoogle Scholar
• BRUMBACK RA, WEINBERG WA: Mania in childhood. II. Therapeutic trial of lithium carbonate and further description of manic-depressive illness in children. Am. J. Dis. Child (1977) 131(10):1122-1126.
   Google Scholar
• GELLER B, COOPER TB, SUN K et al.: Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J. Am. Acad. Child Adolesc. Psychiatry (1998) 37(2):171-178.
   PubMed Web of Science ®Google Scholar
• GELLER B, COOPER TB, ZIMERMAN B et al.: Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study. J. Affect. Disord. (1998) 51(2):165-175.
   PubMedGoogle Scholar
• KOWATCH RA, SUPPES T, CARMODY TJ et al.: Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39(6):713-720.
   PubMed Web of Science ®Google Scholar
• FRAZIER JA, BIEDERMAN J, TOHEN M et al.: A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. (2001) 11(3):239-250.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, MICK E, WOZNIAK J et al.: An open-label trial of risperidone in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. (2005) 15(2):311-317.
   PubMed Web of Science ®Google Scholar
• DELBELLO MP, KOWATCH RA, ADLER CM et al.: A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(3):305-313.
   PubMed Web of Science ®Google Scholar
• DELBELLO MP, SCHWIERS ML, ROSENBERG HL, STRAKOWSKI SM: A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(10):1216-1223.
   PubMed Web of Science ®Google Scholar
• SCHEFFER RE, KOWATCH RA, CARMODY T, RUSH AJ: Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am. J. Psychiatry (2005) 162(1):58-64.
   PubMed Web of Science ®Google Scholar
• GALANTER CA, CARLSON GA, JENSEN PS et al.: Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J. Child Adolesc. Psychopharmacol. (2003) 13(2):123-136.
   PubMed Web of Science ®Google Scholar
• CARLSON GA, LONEY J, SALISBURY H, KRAMER JR, ARTHUR C: Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study. J. Child Adolesc. Psychopharmacol. (2000) 10(3):175-184.
   PubMed Web of Science ®Google Scholar
• HAH M, CHANG K: Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J. Child Adolesc. Psychopharmacol. (2005) 15(6):996-1004.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, WILENS T, MICK E et al.: Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36(1):21-29.
   PubMed Web of Science ®Google Scholar
• MANNUZZA S, KLEIN RG, BESSLER A, MALLOY P, LAPADULA M: Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch. Gen. Psychiatry (1993) 50(7):565-576.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, WILENS T: Does stimulant treatment lead to substance use disorders? J. Clin. Psychiatry (2003) 64(Suppl. 11):9-13.
   PubMed Web of Science ®Google Scholar
• RIGGS PD, HALL SK, MIKULICH-GILBERTSON SK, LOHMAN M, KAYSER A: A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(4):420-429.
   PubMed Web of Science ®Google Scholar
• SULLIVAN MA, RUDNIK-LEVIN F: Attention deficit/hyperactivity disorder and substance abuse. Diagnostic and therapeutic considerations. Ann. NY Acad. Sci. (2001) 931:251-270.
   PubMed Web of Science ®Google Scholar
• SCHUBINER H, SAULES KK, ARFKEN CL et al.: Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp. Clin. Psychopharmacol. (2002) 10(3):286-294.
   Google Scholar